Life-extension therapy: Rosiglitazone, an antidiabetic medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 2/January/2017, 6.15 am

Vitamin-based PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: δ-tocotrienol (a form of Vitamin-E) inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene 1/January/2017, 11.45 pm
January 1, 2017
Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: Pioglitazone (trade name: Actos), an antihyperglycemic drug, increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 2/January/2017, 8.26 am
January 2, 2017
Show all

What they say?

A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports, for the first time, that: Life-extension therapy:
Rosiglitazone, an antidiabetic medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span


Research findings to Therapeutic opportunity: 

This study reveals, for the first time, the known anti-diabetic drug Rosiglitazone’s unknown function as a lifespan-promoter. Rosiglitazone, by  increasing  the expression of its target gene, it may suppress Ribosomal protein S6 kinase 1 (p70S6 Kinase) expression. Thereby, it may promote: (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity (fig. 1).   

rosiglitazone-suppresses-p70-s6-kinase-expression-and-extends-lifespan

Fig 1. The antidiabetic drug Rosiglitazone may function as a longevity promoter by suppressing the expression of p70 S6 Kinase

price-100[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “Rosiglitazone either alone or or in combination with any of the known longevity-promoting compound(s) may be used to extend the lifespan of an individual (fig. 1).


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed Information: How PAPD5 decreases the expression of p70 S6 Kinase and promotes mammalian life span?

# Research cooperation

Amount: $100 #


References:

CitationBoominathan, L.,  Life-extension therapy: Rosiglitazone, an antidiabetic medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 2/January/2017, 6.15 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.